"But being a public company--that's CVM.
The public company is CVM,so the $ would show up on their balance sheet or if it's a large sum, and a material change, in the 8K.
Greater than $50M ? Keep dreaming.
CEL-SCI initially retained inVentiv, a clinical research organization, to conduct the Phase III Clinical Trial of CEL-SCI's investigational drug Multikine(C) (Leukocyte Interleukin, Injection). CEL-SCI terminated inVentiv in or about March 2013 and replaced it with two clinical research organizations, Aptiv Solutions, Inc. and Ergomed Clinical Research Ltd. CEL-SCI's arbitration claim is initiated under the Commercial Rules of the American Arbitration Association, pursuant to the parties' contract, and alleges (i) breach of contract, (ii) fraud in the inducement, and (iii) common law fraud. In an amended statement of claim, CEL-SCI has also alleged professional malpractice against inVentiv. CEL-SCI seeks at least $50 million in damages.
inVentiv, which previously asserted (i) a breach of contract counterclaim against CEL-SCI, seeking at least $2 million in damages for services allegedly performed by inVentiv, has alleged additional counterclaims against CEL-SCI, for
(ii) breach of contract, seeking at least $1 million in damages for allegedly using inVentiv's name in connection with publications and promotions, which inVentiv claims breached a provision in the parties' contract; (iii) opportunistic breach, restitution and unjust enrichment, seeking at least $20 million in disgorgement of alleged unjust profits allegedly made by CEL-SCI as a result of the purported breaches referenced in subsection (ii); and (iv) defamation, seeking at least $1 million in damages for allegedly defamatory statements made about inVentiv. CEL-SCI believes inVentiv's counterclaims are meritless and intends to vigorously defend against them.
As a result, the arbitration hearing (the arbitration equivalent of a trial), which was previously scheduled for May 4, 2015, has been tentatively rescheduled for October 27, 2015 through November 17, 2015. The arbitrator has instructed the parties to hold this time period free on their calendars.
Although the arbitrator has allowed both parties to supplement their claims, inVentiv has moved to dismiss CEL-SCI's additional claim for professional malpractice, which CEL-SCI will vigorously oppose.
hey cabbie..... "but, being a public company, ".... What is the trading symbol? What exchange does it trade on? What is the date of the last 10K ?
How long has inventiv been in business ??
How long has inventiv been a CRO ?????
"both parties agree not to disclose the merits of the suit or the amounts." ????
CVM is a publicly traded stock and would be required to report any material change via an 8K.
"(whether it's $2m , $20M or another amount)"???? By "another amount" could that be , $50M ? Maybe more?
Sentiment: Strong Buy
What I'm not getting here is this;
For $50m there are some pretty serious accusations being made, right?
And, knowing that a negative outcome for Inventive could be disastrous for them; What company would use them if they lose this lawsuit?
Therefore, we should be hearing this is settled outside of arbitration and both parties agree not to disclose the merits of the suit or the amounts.
I will be surprised at any other outcome, but, being a public company, the amount paid to CVM (whether it's $2m , $20M or another amount)will show up on their balance sheet, right?
Just some thoughts......
How is it possible that a company can be in around for so long and be in a phase 3 clinical and be a rip off? Sounds like there are people that just like to stir the pot. Wish there was a board you could get straight talk.
hey up..... The leaning tower of BABEL , is a born today ( from a few days ago) poster.
Several years ago there was a poster doing the same thing, double speak BABEL nonsense, on the ACEL M/B.
Is he saying CVM is a late stage bio with a soon to be completed P3 with a very large ANNUAL H&N patient base????
Every day is one day closer to 880.
Sentiment: Strong Buy
So, my newly born friend you choose to be obtuse instead of obdurate. BAIT ???
Short selling is selling shares one doesn't have to take a negative bet. There is no limit to the losses a short selling can take if a stock should say..............gap up $2.00 one fine morning.
Sentiment: Strong Buy
Something that is not mentioned all that often;
In the world of Biotechs, employees come and go.
Eyal Talor, Patricia Prichep, Daniel Zimmerman, Gavin DeWindt.
These are folks who have worked for CelSci for between 15-25 years (give or take) each.
People can spin it many different ways, but having your chief scientific officer and core employees around this long says a lot. We have to appreciate that for what it's worth.
Just sayin, and I don't take it lightly.
#6. BAIT ???????